Aquestive Therapeutics Inc — Quarterly Cash Flow (NASDAQ:AQST) | MetaTrader

Open full chart

Financials

Overview Estratto Conto Statistics Dividends

Quarterly Annual

Total assets 109.96 M101.42 M102.23 M93.7 M163.56 M Total liabilities 155.38 M161.58 M163.16 M166.29 M167.67 M Total equity 45.42 M60.16 M60.93 M72.59 M4.11 M Total liabilities & shareholders' equities 109.96 M101.42 M102.23 M93.7 M163.56 M Total debt ————— Net debt —————

Notizie

Aquestive Therapeutics alla Conferenza Oppenheimer: Approfondimenti Strategici su Anaphylm

Aquestive Therapeutics at Oppenheimer Conference: Strategic Insights on Anaphylm

Aquestive nomina l’esperto di allergie Dr. Greenhawt come chief medical officer

Aquestive appoints allergy expert Dr. Greenhawt as chief medical officer

H.C. Wainwright conferma il rating Buy su Aquestive dopo la risposta della FDA

H.C. Wainwright reiterates Buy rating on Aquestive stock after FDA response

Aquestive Therapeutics, Inc. (AQST) Discusses FDA Complete Response Letter and Next Steps for Anaphylm Epinephrine Sublingual Film - Slideshow (NASDAQ:AQST) 2026-02-03

Disney, Micron Tech among market cap stock movers on Monday

Aquestive Therapeutics, Inc. (AQST) Discusses FDA Complete Response Letter and Next Steps for Anaphylm Epinephrine Sublingual Film Transcript

What's Going On With Aquestive Therapeutics Stock Today? - Aquestive Therapeutics (NASDAQ:AQST)

Il titolo di Aquestive sale nonostante la lettera di risposta della FDA per Anaphylm

Aquestive stock rises despite FDA complete response letter for Anaphylm